JPWO2019215063A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019215063A5 JPWO2019215063A5 JP2020562662A JP2020562662A JPWO2019215063A5 JP WO2019215063 A5 JPWO2019215063 A5 JP WO2019215063A5 JP 2020562662 A JP2020562662 A JP 2020562662A JP 2020562662 A JP2020562662 A JP 2020562662A JP WO2019215063 A5 JPWO2019215063 A5 JP WO2019215063A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- agonist
- composition according
- composition
- nac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- DLSWIYLPEUIQAV-CCUURXOWSA-N Semaglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DLSWIYLPEUIQAV-CCUURXOWSA-N 0.000 claims 3
- 229950011186 Semaglutide Drugs 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 229960003966 nicotinamide Drugs 0.000 claims 3
- 235000005152 nicotinamide Nutrition 0.000 claims 3
- 239000011570 nicotinamide Substances 0.000 claims 3
- 108010060325 semaglutide Proteins 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 101710042131 GCG Proteins 0.000 claims 2
- 102100003818 GCG Human genes 0.000 claims 2
- 101700071595 GRZ1 Proteins 0.000 claims 2
- 101700078733 ZGLP1 Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003752 hydrotrope Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Claims (13)
ｉｉ）Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸（ＮＡＣ）の塩と、
ｉｉｉ）ニコチンアミドであるヒドロトロープと、を含む、組成物。 i) GLP-1 agonist and
ii) Salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid (NAC),
iii) A composition comprising a hydrotrope , which is a nicotinamide .
ｉｉ）Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸（ＮＡＣ）の塩、例えば、ＮＡＣのナトリウム塩（ＳＮＡＣ）、
ｉｉｉ）ニコチンアミド、および
ｉｖ）潤滑剤からなる、請求項１～８のいずれか一項に記載の組成物。 i) GLP-1 agonists such as semaglutide, GLP-1 agonist B, or GLP-1 agonist C,
ii) Salts of N- (8- (2-hydroxybenzoyl) amino) caprylic acid (NAC), such as sodium salts of NAC (SNAC),
The composition according to any one of claims 1 to 8, comprising iii) nicotinamide and iv) a lubricant.
ｉ）０．１～３０ｍｇ、例えば０．１～２０ｍｇのＧＬＰ－１アゴニスト、例えば、セマグルチド、ＧＬＰ－１アゴニストＢ、またはＧＬＰ－１アゴニストＣ、
ｉｉ）５０～６００ｍｇのＮ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸（ＮＡＣ）の塩、例えば、前記ＮＡＣのナトリウム塩（ＳＮＡＣ）、および
ｉｉｉ）２０～２００ｍｇのニコチンアミド、
ｉｖ）０～１０ｍｇの潤滑剤を含む、請求項１～１０のいずれか一項に記載の組成物。 The unit dose is
i) 0.1-30 mg, eg 0.1-20 mg GLP-1 agonists such as semaglutide, GLP-1 agonist B, or GLP-1 agonist C,
ii) 50-600 mg of salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid (NAC), eg, the sodium salt of NAC (SNAC), and iii) 20-200 mg of nicotinamide.
iv) The composition according to any one of claims 1 to 10 , comprising 0 to 10 mg of a lubricant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022167761A JP2022191439A (en) | 2018-05-07 | 2022-10-19 | Solid compositions comprising glp-1 agonist and salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171046 | 2018-05-07 | ||
| EP18171046.8 | 2018-05-07 | ||
| PCT/EP2019/061502 WO2019215063A1 (en) | 2018-05-07 | 2019-05-06 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167761A Division JP2022191439A (en) | 2018-05-07 | 2022-10-19 | Solid compositions comprising glp-1 agonist and salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523149A JP2021523149A (en) | 2021-09-02 |
| JPWO2019215063A5 true JPWO2019215063A5 (en) | 2022-05-25 |
| JP7164628B2 JP7164628B2 (en) | 2022-11-01 |
Family
ID=62134107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562662A Active JP7164628B2 (en) | 2018-05-07 | 2019-05-06 | Solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| JP2022167761A Pending JP2022191439A (en) | 2018-05-07 | 2022-10-19 | Solid compositions comprising glp-1 agonist and salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167761A Pending JP2022191439A (en) | 2018-05-07 | 2022-10-19 | Solid compositions comprising glp-1 agonist and salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11622996B2 (en) |
| EP (1) | EP3790575A1 (en) |
| JP (2) | JP7164628B2 (en) |
| KR (1) | KR20210008353A (en) |
| CN (1) | CN112153979A (en) |
| AR (1) | AR115283A1 (en) |
| AU (1) | AU2019264783A1 (en) |
| BR (1) | BR112020021717A2 (en) |
| CA (1) | CA3097944A1 (en) |
| CL (1) | CL2020002797A1 (en) |
| CO (1) | CO2020014570A2 (en) |
| IL (1) | IL277857A (en) |
| MA (1) | MA52556A (en) |
| MX (1) | MX2020011308A (en) |
| PE (1) | PE20211794A1 (en) |
| PH (1) | PH12020551691A1 (en) |
| SG (1) | SG11202009978WA (en) |
| TW (1) | TWI829687B (en) |
| WO (1) | WO2019215063A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642935A (en) * | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | Tirapapotide analogue |
| JP2023524695A (en) | 2020-04-29 | 2023-06-13 | ノヴォ ノルディスク アー／エス | Solid composition comprising GLP-1 agonist and histidine |
| TW202227474A (en) | 2020-12-18 | 2022-07-16 | 丹麥商諾佛 儂迪克股份有限公司 | Co-agonists of the glp-1 and amylin receptors |
| CN113171446B (en) * | 2021-05-06 | 2022-03-29 | 合肥天汇孵化科技有限公司 | Liraglutide compositions and uses thereof |
| WO2022268213A1 (en) * | 2021-06-25 | 2022-12-29 | 甘李药业股份有限公司 | Pharmaceutical composition containing glp-1 compound |
| WO2023065231A1 (en) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
| TW202346324A (en) | 2022-05-10 | 2023-12-01 | 丹麥商諾佛 儂迪克股份有限公司 | Prodrugs and uses thereof |
| WO2024008904A2 (en) * | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382574A (en) | 1989-12-21 | 1995-01-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| DK39892D0 (en) | 1992-03-25 | 1992-03-25 | Bernard Thorens | PEPTIDE |
| US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| AU4298596A (en) * | 1994-12-23 | 1996-07-19 | Novo Nordisk A/S | Protracted glp-1 compositions |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE19530865A1 (en) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Active ingredient and agent for parenteral nutrition |
| UA72181C2 (en) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Derivatives of glucanolike peptide-1 |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| ATE466027T1 (en) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | DERIVATIVES OF GLP-1 ANALOGUE |
| JP2002506792A (en) | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | N-terminal modified GLP-1 derivative |
| AU2610799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates |
| US6440930B1 (en) | 1998-09-17 | 2002-08-27 | Eli Lilly And Company | Protein formulations |
| DE60023841T2 (en) | 1999-02-05 | 2006-05-24 | Emisphere Technologies, Inc. | PROCESS FOR PREPARING ALKYLATED SALICYLAMIDE |
| JP2002542183A (en) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | Moldable dry pharmaceutical formulation |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| AU2002308706A1 (en) | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| ES2614603T3 (en) | 2002-02-20 | 2017-06-01 | Emisphere Technologies, Inc. | GLP-1 Molecule Administration Procedure |
| WO2004104018A2 (en) * | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compositions for delivering peptide yy and pyy agonists |
| CN1787830A (en) * | 2003-05-14 | 2006-06-14 | 爱密斯菲尔科技公司 | Compositions for delivering peptide YY and PYY agonists |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| RU2006120079A (en) | 2003-12-18 | 2008-01-27 | Ново Нордиск А/С (DK) | Glucagon-like Peptides-1 Derivatives (GLP-1) |
| CA2550050A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| MXPA06011425A (en) | 2004-03-31 | 2007-03-12 | Johnson & Johnson | Human glp-1 mimetibodies, compositions, methods and uses. |
| CN1968919A (en) * | 2004-04-16 | 2007-05-23 | 爱密斯菲尔科技公司 | 8-(2-hydroxyphenoxy) octyldiethanolamine and salts thereof for delivery of active agents |
| US8039018B2 (en) * | 2004-05-06 | 2011-10-18 | Emisphere Technologies, Inc. | Solid dosage form of wetted heparin |
| TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| KR20070029247A (en) | 2004-07-08 | 2007-03-13 | 노보 노르디스크 에이/에스 | Polypeptide protracting tags |
| BRPI0513101A (en) * | 2004-07-12 | 2008-04-29 | Emisphere Tech Inc | dosage unit form for buccal administration, use of the dosage unit form and method for preparing the dosage unit form |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| WO2006037811A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted exendin-4 compounds |
| EP2168982A1 (en) | 2004-12-22 | 2010-03-31 | Eli Lilly & Company | GLP-1 analog fusion protein formulations |
| EP1843788A4 (en) | 2004-12-22 | 2009-11-18 | Centocor Ortho Biotech Inc | Glp-1 agonists, compositions, methods and uses |
| US20080153779A1 (en) | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
| KR20070120112A (en) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | Extended glp-1 compounds |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2006235183B2 (en) | 2005-04-08 | 2011-02-10 | Amylin Pharmaceuticals, Llc | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| EP1968645A4 (en) | 2005-12-22 | 2009-11-04 | Centocor Ortho Biotech Inc | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8679540B2 (en) | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| MX2009000748A (en) | 2006-07-18 | 2009-03-31 | Centocor Inc | Human glp-1 mimetibodies, compositions, methods and uses. |
| WO2008019147A2 (en) | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| EP2068910A2 (en) | 2006-08-04 | 2009-06-17 | Amylin Pharmaceuticals, Inc. | Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| CN101506147B (en) | 2006-09-07 | 2012-03-21 | 霍夫曼-拉罗奇有限公司 | A process for the manufacture of snac (n-(8-[2-hydroxybenzoyl]-amino) salcaprozate sodium) |
| US20100069410A1 (en) | 2006-12-01 | 2010-03-18 | Emisphere Technologies Inc. | acyclovir formulations |
| AR064623A1 (en) | 2006-12-21 | 2009-04-15 | Centocor Inc | USE OF LONG-TERM GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES |
| US20100080829A1 (en) | 2007-04-11 | 2010-04-01 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| EP1980245A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Bilayer lyophilized pharmaceutical compositions and methods of making and using same |
| GB0707662D0 (en) * | 2007-04-20 | 2007-05-30 | Astrazeneca Ab | Chemical compounds |
| CN101842109B (en) | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | Peptides derivatized with A-B-C-D- and their therapeutical use |
| JP2010538049A (en) | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー／エス | Cleaved GLP-1 derivatives and therapeutic uses thereof |
| ES2672770T3 (en) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivatives of glucagon-like peptide-1 and its pharmaceutical use |
| CN102026666B (en) | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发（河北）有限公司 | Formulation of insulinotropic peptide conjugates |
| JP2009274983A (en) | 2008-05-14 | 2009-11-26 | Kowa Co | Oral pharmaceutical composition containing nicotinic amide |
| EP2303226B1 (en) | 2008-06-25 | 2016-03-23 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
| CA2734442C (en) | 2008-08-18 | 2016-08-16 | Oramed Ltd | Methods and compositions for oral administration of proteins |
| ES2809178T5 (en) | 2008-09-04 | 2024-04-29 | Amylin Pharmaceuticals Llc | Sustained release formulations using non-aqueous carriers |
| US8425968B2 (en) | 2009-06-19 | 2013-04-23 | Pepsico., Inc. | Beverage preservative system containing pimaricin-cyclodextrin complex |
| US20120065255A1 (en) | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
| RU2537239C2 (en) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Pharmaceutical composition containing agonist glp-1, insulin and methionine |
| PE20121316A1 (en) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST AND METHIONINE |
| EP3000482B1 (en) | 2009-12-16 | 2021-04-21 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP2512454A2 (en) | 2009-12-16 | 2012-10-24 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| NZ602032A (en) | 2010-02-24 | 2014-11-28 | Emisphere Tech Inc | Oral b12 therapy |
| WO2011109784A1 (en) | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Formulation of insulinotropic peptide conjugates |
| US9006178B2 (en) | 2010-11-09 | 2015-04-14 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives with a linker |
| RU2600440C3 (en) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT |
| CN102718858B (en) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof |
| MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| EP2723359A4 (en) | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| EP2729481B1 (en) | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| RS57727B1 (en) | 2012-03-22 | 2018-12-31 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
| RS64942B1 (en) * | 2012-03-22 | 2024-01-31 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
| ES2871328T3 (en) * | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Tablet formulation comprising a peptide and a delivery agent |
| EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | Pharmaceutical preparation for injection |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| KR20150096433A (en) | 2012-12-21 | 2015-08-24 | 사노피 | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| AU2014261336B2 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| CN103405753B (en) | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086732A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
| AR099569A1 (en) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE |
| US10689429B2 (en) | 2014-04-07 | 2020-06-23 | Novo Nordisk A/S | Double-acylated GLP-1 compounds |
| EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
| EP3250190A1 (en) | 2015-01-29 | 2017-12-06 | Novo Nordisk A/S | Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating |
| WO2016203495A1 (en) | 2015-06-16 | 2016-12-22 | Sun Pharma Advanced Research Company Limited | Long acting liraglutide compositions |
| EP3359181A1 (en) | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide drugs |
| CN108699126B (en) | 2016-03-03 | 2022-12-06 | 诺和诺德股份有限公司 | GLP-1 derivatives and uses thereof |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| BR112019008565A2 (en) | 2016-10-31 | 2019-07-09 | Suda Ltd | active agent distribution in the mucosa |
| TWI797133B (en) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | Solid compositions for oral administration |
| BR112020014624A2 (en) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT) |
| DK3774862T3 (en) | 2018-04-05 | 2022-09-05 | Sun Pharmaceutical Ind Ltd | New GLP-1 analogs |
-
2019
- 2019-05-03 TW TW108115351A patent/TWI829687B/en active
- 2019-05-06 MX MX2020011308A patent/MX2020011308A/en unknown
- 2019-05-06 US US17/053,511 patent/US11622996B2/en active Active
- 2019-05-06 CA CA3097944A patent/CA3097944A1/en active Pending
- 2019-05-06 AR ARP190101193A patent/AR115283A1/en unknown
- 2019-05-06 EP EP19720693.1A patent/EP3790575A1/en active Pending
- 2019-05-06 WO PCT/EP2019/061502 patent/WO2019215063A1/en unknown
- 2019-05-06 SG SG11202009978WA patent/SG11202009978WA/en unknown
- 2019-05-06 MA MA052556A patent/MA52556A/en unknown
- 2019-05-06 PE PE2020001685A patent/PE20211794A1/en unknown
- 2019-05-06 JP JP2020562662A patent/JP7164628B2/en active Active
- 2019-05-06 AU AU2019264783A patent/AU2019264783A1/en active Pending
- 2019-05-06 CN CN201980031030.XA patent/CN112153979A/en active Pending
- 2019-05-06 BR BR112020021717-4A patent/BR112020021717A2/en unknown
- 2019-05-06 KR KR1020207033262A patent/KR20210008353A/en active Search and Examination
-
2020
- 2020-10-07 IL IL277857A patent/IL277857A/en unknown
- 2020-10-13 PH PH12020551691A patent/PH12020551691A1/en unknown
- 2020-10-28 CL CL2020002797A patent/CL2020002797A1/en unknown
- 2020-11-24 CO CONC2020/0014570A patent/CO2020014570A2/en unknown
-
2022
- 2022-10-19 JP JP2022167761A patent/JP2022191439A/en active Pending
- 2022-11-16 US US17/988,271 patent/US20230087952A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6625773B2 (en) | How to treat Parkinson's disease | |
| EP0252290B1 (en) | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | |
| US8030314B2 (en) | Use of 2h-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable acid addition salts | |
| JP5395052B2 (en) | Compositions and methods for treating inflammation | |
| US10065944B2 (en) | Administration regime for nitrocatechols | |
| JP2015537002A5 (en) | ||
| AU2002310813A1 (en) | Flibanserin for the treatment of extrapyramidal movement disorders | |
| RU2600440C3 (en) | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT | |
| JP2004532272A5 (en) | ||
| KR102020939B1 (en) | Systems, methods, and formulations for treating cancer | |
| JP2011502997A5 (en) | ||
| JPWO2019215063A5 (en) | ||
| JP2009514912A5 (en) | ||
| JP2020529440A5 (en) | ||
| JP5403935B2 (en) | Oral chronic pain prevention or treatment agent | |
| JP5542309B2 (en) | Oral pharmaceutical composition | |
| WO2007149815A1 (en) | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | |
| WO2007069925A2 (en) | Non-neurotoxic recreational drugs and a method of treating recreational drug abuse | |
| JP5053665B2 (en) | Hypnotic pharmaceutical composition | |
| TWI290831B (en) | Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
| JPWO2021023811A5 (en) | ||
| CN1496265A (en) | Medicine for fighting against sexual dysfunction | |
| JP6781561B2 (en) | Pharmaceutical composition containing a propionic acid non-steroidal anti-inflammatory drug | |
| JP6100510B2 (en) | Anti-cold medicine | |
| RU2020138000A (en) | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT |